Monday, January 16, 2017 11:11:10 AM
“We believe that our success in obtaining broad insurance coverage for our cancer tests reflects the fact that by design, our portfolio focuses on actionable genetic mutations that are included in current cancer guidelines and are of practical utility to patients and their oncologists, providing insight into which drugs might be most appropriate for the patient at that point in their treatment,” said Paul Kinnon, President and CEO of Transgenomic. “Since they are based on our unique ICE COLD-PCR™ technology, our tests also work exceptionally well with either blood or tissue samples, enabling their use with almost any cancer patient at all stages of the disease. We are pleased with the breadth of coverage to date and expect to increase insurer coverage in the new year, as we also work to educate doctors and patients about the advantages of our growing menu of cancer tests.”
Last month, Transgenomic announced the launch of its comprehensive Multiplexed ICE COLD-PCR Non-Small Cell Lung Cancer (NSCLC) Analysis panel that covers the key actionable mutations that are relevant to the targeted treatment of NSCLC, one of the most common types of cancer and the leading cause of cancer deaths in the US. It followed the earlier launch of tests for lung cancer and for detection of KRAS and NRAS mutations in colorectal cancer. Additional cancer tests are in development. Transgenomic’s cancer tests are available for clinical diagnostic use through the company’s CLIA laboratory.
DUKE BASKETBALL and NOTRE DAME FOOTBALL
Recent PRPO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:01:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:20:29 PM
- Precipio Secures a short-term $500K Credit Facility • GlobeNewswire Inc. • 05/06/2024 09:00:00 PM
- Precipio Announces Year end 2023 Shareholder Update Call • GlobeNewswire Inc. • 03/25/2024 09:00:00 PM
- Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY • GlobeNewswire Inc. • 02/13/2024 03:00:00 PM
- Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer • GlobeNewswire Inc. • 02/06/2024 03:00:00 PM
- Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter • GlobeNewswire Inc. • 01/23/2024 03:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/19/2024 09:05:44 PM
- Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan • GlobeNewswire Inc. • 01/17/2024 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:33:26 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 10:01:11 PM
- Precipio Announces Christina Valauri joins the Board of Directors • GlobeNewswire Inc. • 01/02/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 10:00:22 PM
- Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024 • GlobeNewswire Inc. • 12/14/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:15:16 PM
- Precipio Announces Q3-2023 Shareholder Update Call • GlobeNewswire Inc. • 11/16/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:03:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 08:30:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:30:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/26/2023 08:30:25 PM
- Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022 • GlobeNewswire Inc. • 10/18/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 08:34:18 PM
- Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023 • GlobeNewswire Inc. • 10/03/2023 02:00:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM